Maze Therapeutics, a South San Francisco, CA-based company focused on translating genetic insights into new medicines, received an investment from City Hill Ventures.
The amount of the deal was not disclosed.
In conjunction with the funding, Jonathan Lim, M.D., founder and managing partner at City Hill Ventures, joined the company’s board of directors.
In addition to his role at City Hill, Dr. Lim is a venture partner at ARCH Venture Partners, chairman, chief executive officer and co-founder at Erasca, and chairman and co-founder at Boundless Bio.
Led by Jason Coloma, Ph.D., chief executive officer, Maze Therapeutics is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for a number of genetically defined diseases. The company is focused on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.
The platform reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be best targeted with drug therapies.
Maze was launched in 2019 by Third Rock Ventures, with funding from ARCH Venture Partners, GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments, City Hill and other undisclosed investors.